Author

Karen DeMairo

Observed names: K. DeMairo, Karen Demairo

Institution: Blood Cancer United

Observed institution: Blood Cancer United

ORCID: 0009-0008-0741-5010

Observed ORCID: 0009-0008-0741-5010

OpenAlex ID: A5070420539

Proceedings From the Second Reimagining Caregiver Workshop: Addressing Caregiver Requirements for Hematopoietic Cell Transplant

2025 · Jaime M. Preussler, Anna M. DeSalvo, et al. · Transplantation and Cellular Therapy · 5

HSR25-174: Impact of Adverse Events on Quality of Life in Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors – Results From the Survey on Humanistic Burden of Intolerance to First or Second TKIs (SHIFT) Study

2025 · Kathryn E. Flynn, Joan Clements, et al. · Journal of the National Comprehensive Cancer Network · 4

Preparing Patients to Communicate with Their Doctors About Clinical Trials as a Treatment Option: Impact of a Novel Video Intervention for Patients with a Blood Cancer and Their Caregivers

2023 · Taylor S. Vasquez, Susan Eggly, et al. · Journal of Cancer Education · 3

Perceptions about participation in cancer clinical trials in New York state

2015 · Danielle Crookes, Chang Wang, et al. · The Journal of Community and Supportive Oncology · 3

Impact of Adverse Events on Health-Related Quality of Life in Patients with Chronic Myeloid Leukemia (CML) Treated with Tyrosine Kinase Inhibitors (TKIs) - Early Results of the Survey on Humanistic Burden of Intolerance to First or Second TKIs (SHIFT) Study

2024 · Kelly Schoenbeck, Joan Clements, et al. · Blood · 2

Adverse events, quality of life, and work impairment in patients with chronic myeloid leukemia (CML)—a survey of first- and second-line tyrosine kinase inhibitor (TKI) intolerance in the US

2026 · Kelly Schoenbeck, David Wei, et al. · Leukemia & lymphoma/Leukemia and lymphoma

The humanistic burden of patients with chronic myeloid leukemia (CML) treated with first line (1L) tyrosine kinase inhibitors (TKIs)

2025 · Kelly Schoenbeck, Joan Clements, et al. · Blood

POSTER: CML-1030 Quality of Life and Work Impacts Among Caregivers of Patients With Chronic Myeloid Leukemia: A Caregiver Survey in the US

2025 · Kathryn Flynn, Joan Clements, et al. · Clinical Lymphoma Myeloma & Leukemia

POSTER: CML-969 Impact of Adverse Events (AEs) on Health-Related Quality of Life (HRQOL) in Chronic Myeloid Leukemia (CML): Results From the Patient Survey on Humanistic Burden of Intolerance to First or Second Tyrosine Kinase Inhibitors (TKIs) SHIFT Study in the US

2025 · Kelly Schoenbeck, Joan Clements, et al. · Clinical Lymphoma Myeloma & Leukemia

CML-969: Impact of Adverse Events (AEs) on Health-Related Quality of Life (HRQOL) in Chronic Myeloid Leukemia (CML): Results From the Patient Survey on Humanistic Burden of Intolerance to First or Second Tyrosine Kinase Inhibitors (TKIs) SHIFT Study in the US

2025 · Kelly Schoenbeck, Joan Clements, et al. · Clinical Lymphoma Myeloma & Leukemia

CML-1030: Quality of Life and Work Impacts Among Caregivers of Patients With Chronic Myeloid Leukemia: A Caregiver Survey in the US

2025 · Kathryn Flynn, Joan Clements, et al. · Clinical Lymphoma Myeloma & Leukemia

HSR25-182: Patient-Physician Communication About Adverse Events and Impact on Quality of Life to Foster Shared Decision-Making in Chronic Myeloid Leukemia

2025 · Kathryn E. Flynn, Joan Clements, et al. · Journal of the National Comprehensive Cancer Network

Understanding Myeloma-Related Information Needs and Communication Preferences Within Black American Communities: An Exploratory Study

2024 · N. S. Esquivel, J. P. Tzeng, et al. · Journal of Cancer Education

Patient beliefs and behaviors concerning clinical trials for blood cancers: Outcomes from live-online education.

2019 · Anne Roc, Wendy Turell, et al. · Journal of Clinical Oncology

New York state health care provider participation in clinical trials: a brief report

2016 · Pathu Sriphanlop, Danielle M Crookes, et al. · journal of cancer therapeutics and research

Works count: 15

Citation count: 17

H-index: 3

I10-index: